rc48-adc
ALK-Positive Anaplastic Large Cell Lymphoma
BeiGeneantibody_drug_conjugatePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the ALK-Positive Anaplastic Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab BeiGene | Phase 2 | B |
Pyrotinib BeiGene | Phase 2 | B |
cc-5013 Huiqiang Huang | Phase 1/2 | CCC |
Capecitabine Huiqiang Huang | Phase 1/2 | CCC |
Toripalimab Huiqiang Huang | Phase 1/2 | CCC |
(+)-VINCRISTINE Huiqiang Huang | Phase 1/2 | CCC |
Rivoceranib Huiqiang Huang | Phase 1/2 | CCC |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Huiqiang Huang | Phase 1/2 | CCC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →